Effects and Mechanisms of Yangyin Yiqi Huoxue Formula on the Oral Microecology in Sjögren's Syndrome Model Mice

WU Fangping, LU Wenwen, WU Danbin, ZHOU Yangqing, LU Haifeng, YING Lixiong, WU Guolin

Abstract

Objective 

 To investigate the effect of the Yangyin Yiqi Huoxue formula on the oral microecology in a mouse model of Sjögren's syndrome (SS), and to explore the underlying mechanisms.

Methods 

 A total of 12 8-week-old non-obese diabetic (NOD) mice were randomly assigned to a model group, a traditional Chinese medicine (TCM) group, and a hydroxychloroquine (HCQ) group, with 4 mice in each group. In addition, 4 BALB/c mice were used as the normal control group. The TCM group was administered Yangyin Yiqi Huoxue formula (15 g/[kg·d]) via gavage and the HCQ group received HCQ (0.08 g/[kg·d]) via gavage. The normal control and model groups were maintained under standard feeding conditions without intervention. After 8 weeks of treatment, saliva samples were collected for 16S rRNA gene sequencing to analyze the oral microbiota. Alpha diversity, beta diversity, and functional prediction analyses were performed.

Results 

 Alpha diversity analysis showed that the Yangyin Yiqi Huoxue formula significantly increased oral microbiome diversity in NOD mice (P < 0.05). Species composition analysis indicated that the formula increased the abundance of the phylum Proteobacteria and decreased the abundance of the phylum Firmicutes (P < 0.01), while HCQ led to an abnormal decrease in the abundance of the phylum Firmicutes. Beta diversity analysis revealed distinct microbial clustering in the treatment groups and the model group, with the TCM group showing clustering in the phylum Proteobacteria and exhibiting lower intragroup dispersion than the HCQ group did. According to the functional prediction analysis, both the TCM and HCQ groups demonstrated regulatory potential in terms of amino acid transport and metabolism, transcription, and other related functions. KEGG analysis found greater microbial enrichment in cellular processes, environmental information processing, and disease-related pathways in the TCM group compared to the HCQ group (P < 0.05).

Conclusion 

 The Yangyin Yiqi Huoxue formula can restore oral microbiome diversity and improve the colony structure in in a mouse model of SS, providing experimental evidence for the advantages of TCM in regulating oral microecological functions.

 

Keywords: Non-obese diabetic mice, Yangyin Yiqi Huoxue formula, Oral microbiota, Sequence analysis, Sjögren's syndrome

 

Full Text:

PDF


References


THORLACIUS G E, BJÖRK A, WAHREN-HERLENIUS M. Genetics and epigenetics of primary Sjögren syndrome: implications for future therapies. Nat Rev Rheumatol, 2023, 19(5): 288-306. doi: 10.1038/s41584-023-00932-6.

YURA Y, HAMADA M. Outline of salivary gland pathogenesis of Sjögren's syndrome and current therapeutic approaches. Int J Mol Sci, 2023, 24(13): 11179. doi: 10.3390/ijms241311179.

PERELLA C, STEENACKERS M, ROBBINS B, et al. Patient experience of Sjögren's disease and its multifaceted impact on patients' lives. Rheumatol Ther, 2023, 10(3): 601-614. doi: 10.1007/s40744-023-00531-7.

LI X X, MAITIYAER M, TAN Q, et al. Emerging biologic frontiers for Sjögren's syndrome: unveiling novel approaches with emphasis on extra glandular pathology. Front Pharmacol, 2024, 15: 1377055. doi: 10.3389/fphar.2024.1377055.

BALDINI C, FULVIO G, La ROCCA G, et al. Update on the pathophysiology and treatment of primary Sjögren's syndrome. Nat Rev Rheumatol, 2024, 20(8): 473-491. doi: 10.1038/s41584-024-01135-3.

FOX R I, FOX C M, GOTTENBERG J E, et al. Treatment of Sjögren's syndrome: current therapy and future directions. Rheumatology (Oxford), 2021, 60(5): 2066-2074. doi: 10.1093/rheumatology/kez142. LIU R,

GUO Z, XU H, et al. Traditional Chinese medicine for Sjögren's syndrome: a national survey of attitudes and perceptions among Chinese patients and rheumatologists. BMC Complement Med Ther, 2024, 24(1): 291. doi: 10.1186/s12906-024-04591-2.

DOARÉ E, HÉRY-ARNAUD G, DEVAUCHELLE-PENSEC V, et al. Healthy patients are not the best controls for microbiome-based clinical studies: example of Sjögren's syndrome in a systematic review. Front Immunol, 2021, 12: 699011. doi: 10.3389/fimmu.2021.699011.

SAÚCO C, RUS M J, NIETO M R, et al. Hyposalivation but not Sjögren's syndrome associated with microbial dysbiosis in women. Front Microbiol, 2023, 14: 1240891. doi: 10.3389/fmicb.2023.1240891.

BUSTOS-LOBATO L, RUS M J, SAÚCO C, et al. Oral microbial biomap in the drought environment: Sjogren's syndrome. Mol Oral Microbiol, 2023, 38(5): 400-407. doi: 10.1111/omi.12435.

XIE Y, FAN Y, SU M, et al. Characteristics of the oral microbiota in patients with primary Sjögren's syndrome. Clin Rheumatol, 2024, 43(6): 1939-1947. doi: 10.1007/s10067-024-06958-9.

WANG X, PANG K, WANG J, et al. Microbiota dysbiosis in primary Sjögren's syndrome and the ameliorative effect of hydroxychloroquine. Cell Rep, 2022, 40(11): 111352. doi: 10.1016/j.celrep.2022.111352.

WEI S J, HE Q M, ZHANG Q, et al. Traditional Chinese medicine is a useful and promising alternative strategy for treatment of Sjogren's syndrome: a review. J Integr Med, 2021, 19(3): 191-202. doi: 10.1016/j. joim.2021.01.008.

DÖRNER T, KAUL M, SZÁNTÓ A, et al. Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren's syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial. Ann Rheum Dis, 2024, 83(3): 360-371. doi: 10.1136/ard-2023-224691.

HE W, LU Y, SHI R, et al. Application of omics in Sjögren's syndrome. Inflamm Res, 2023, 72(12): 2089-2109. doi: 10.1007/s00011-023-01797-x.

WEI T T, QIN W, WU F Y, et al. Nursing strategies for oral microecological disorders in primary Sjogren’s syndrome. J Pract Med, 2020, 36(10): 1398-1401. doi: 10.3969/j.issn.1006-5725.2020.10.025.

WU G L, WU N Y, LI T Y, et al. Effect of Chinese herbal medicines for nourishing yin, supplementing qi, and activating blood on reproductive endocrine activity and immune functions in patients with primary Sjögren's syndrome. Chin J Integr Med, 2015, 21(10): 778-783. doi: 10. 1007/s11655-015-2323-y.

WU G L, LI T Y, FAN Y S, et al. Therapeutic effect of Chinese herbal medicine for strengthening qi, nourishing yin, and removing stasis on serum osteopontin and quality of life of patients with primary Sjögren's syndrome. Chin J Integr Med, 2011, 17(9): 710-714. doi: 10.1007/s11655-011-0850-8.

GAO Y, CHEN Y, ZHANG Z, et al. Recent advances in mouse models of Sjögren's syndrome. Front Immunol, 2020, 11: 1158. doi: 10.3389/fimmu. 2020.01158.

FELTEN R, FORAY A P, SCHNEIDER P, et al. Efficacy of BAFF inhibition and B-cell depletion in non-obese diabetic mice as a spontaneous model for Sjögren's disease. RMD Open, 2024, 10(3): e004112. doi: 10.1136/rmdopen-2024-004112.

CHEN C, ZENG P, YAO X, et al. Gut microbiota combined with fecal metabolomics reveals the effects of FuFang Runzaoling on the microbial and metabolic profiles in NOD mouse model of Sjögren's syndrome. BMC Complement Med Ther, 2023, 23(1): 195. doi: 10.1186/s12906-023-04017-5.

PU Y, HE Y, ZHAO X, et al. Depression-like behaviors in mouse model of Sjögren's syndrome: a role of gut-microbiota-brain axis. Pharmacol Biochem Behav, 2022, 219: 173448. doi: 10.1016/j.pbb.2022.173448.

KOBAYASHI R, OGAWA Y, HASHIZUME-TAKIZAWA T, et al. Oral bacteria affect the gut microbiome and intestinal immunity. Pathog Dis, 2020, 78(3): ftaa024. doi: 10.1093/femspd/ftaa024.

LU W W, FU T X, WANG Q, et al. The effect of total glucoside of paeony on gut microbiota in NOD mice with Sjögren's syndrome based on high-throughput sequencing of 16SrRNA gene. Chin Med, 2020, 15: 61. doi: 10. 1186/s13020-020-00342-w.

SHADE A. Announcing the mSystems special collection on microbial dormancy. mSystems, 2024, 9(10): e100524. doi: 10.1128/msystems. 01005-24.

OREN A, GARRITY G M. Valid publication of the names of forty-two phyla of prokaryotes. Int J Syst Evol Microbiol, 2021, 71(10). doi: 10.1099/ijsem.0.005056.

TIERNEY B T, YANG Z, LUBER J M, et al. The landscape of genetic content in the gut and oral human microbiome. Cell Host Microbe, 2019, 26(2): 283-295. doi: 10.1016/j.chom.2019.07.008.

LIN L, WU K H, WANG W M. The mechanism of chloroquine/hydroxychloroquine and its application in stomatological diseases. J Prev Treat Stomatol Dis, 2021, 29(3): 198-201. doi: 10.12016/j.issn.2096-1456. 2021.03.010.

CHACÓN-DULCEY V, LÓPEZ-LABADY J, VILLARROEL-DORREGO M, et al. Oral manifestations associated with antimalarial therapy in patients with systemic lupus erythematosus. Lupus, 2020, 29(7): 761-766. doi: 10.1177/0961203320922620.

PAN Z Y, CHANG Y X, HAN N, et al. Short-term high-dose gavage of hydroxychloroquine changes gut microbiota but not the intestinal integrity and immunological responses in mice. Life Sci, 2021, 264: 118450. doi: 10.1016/j.lfs.2020.118450.

RADAIC A, SHAMIR E R, JONES K, et al. Specific oral microbial differences in proteobacteria and bacteroidetes are associated with distinct sites when moving from healthy mucosa to oral dysplasia-a microbiome and gene profiling study and focused review. Microorganisms, 2023, 11(9): 2250. doi: 10.3390/microorganisms11092250.


Refbacks

  • There are currently no refbacks.